JPRN-jRCT2080220796未知2 期
A Phase II Study of Nimotuzumab in Patients with Unresectable Stage III Non-small Cell Lung Cancer
DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 39 人开始时间: 2009年8月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Patients with unresectable stage IIIA or IIIB of NSCLC
- •Patients who are judged to be suitable for radical radiotherapy
排除标准
- •Patients with another active malignancy
- •Patients who have obvious pulmonary fibrosis or interstitial pneumonia by chest CT-scans
- •Patients with severe or uncontrolled complications
研究者
相似试验
已完成
2 期
Phase II trial of nivolumab in patients with unresectable or recurrent thymic carcinoma; PRIMER trialthymic carcinomaJPRN-UMIN000022007ational Cancer Center15
招募中
2 期
Phase II study of ramucirumab for the patients with advanced hepatocellular carcinoma previously treated with lenvatinibHepatocellular carcinomaJPRN-jRCT1041190083Yamashita Tatsuya33
已完成
2 期
A clinical trial of nivolumab in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (NCCH1510,OSCAR trial)clear cell sarcoma and alveolar soft part sarcomaJPRN-UMIN000023665ational Cancer Center20
进行中（未招募）
2 期
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarkerJPRN-jRCTs031180013Kagamu Hiroshi60
已完成
不适用
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarkernon-small-cell lung cancerJPRN-UMIN000028468orst East Japan Study Group(NEJSG)60